Albitar et al. successfully treated 21 patients with intravenous bevacizumab for refractory GAVE/SBA bleeding and reported a significant reduction in the need for endoscopic procedures or RBC transfusions and an improvement in median Hb levels at 6–12 months of follow-up [4]. The gene discussed is GSTM1; the disease is gastric antral vascular ectasia.